Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Crohn's Disease
Interventions: AMG 139; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Berlin, New Jersey • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Safety
Interventions: PRV-3279 or placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acne Vulgaris
Interventions: Tazarotene (Patch application in Challenge Phase); Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Obstructive Sleep Apnea, Healthy Subjects
Interventions: Placebo, Lemborexant 10 mg, Lemborexant 25 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 11
States / cities: Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more

Conditions: Healthy Volunteer
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more

Conditions: Healthy
Interventions: Placebo, PF-06818883; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bacterial Infections
Interventions: TP-271, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Risdiplam, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Healthy Volunteer
Interventions: D-2570, Placebo; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HCV Infection
Interventions: ABT-267, Placebo, Blood Sample Collection, Cytochrome P450 inhibitor; Drug · Procedure
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Waukegan, Illinois • San Antonio, Texas

Conditions: Undefined
Interventions: MyMD1, Placebo; Drug
Lead sponsor: TNF Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Systemic Lupos Erythematosus, SLE
Interventions: BIIB068, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: 100 mg CNTO 3157, 300 mg CNTO 3157, 600 mg CNTO 3157, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: PF-04447943, Placebo, Moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pharmacokinetics of ASP4058, Healthy Subjects, Food Effect of ASP4058
Interventions: ASP4058, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miami, Florida • Evansville, Indiana

Conditions: Healthy Volunteers
Interventions: RP7214, Placebo; Drug
Lead sponsor: Rhizen Pharmaceuticals SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Las Vegas, Nevada • Fargo, North Dakota

Conditions: Pharmacokinetics
Interventions: Hutrukin, Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Parapsoriasis, Healthy Volunteers
Interventions: CC-90005, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Subjects
Interventions: AC-170 0.24%, AC-170 Vehicle; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy Volunteers
Interventions: GC021109, Placebo; Drug · Other
Lead sponsor: GliaCure, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232 PIB, GSK2838232 IR1, GSK2838232 IR2, Placebo PIB, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: AZD1305, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Albiglutide 50 mg, Placebo, CCK (Kinevac); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Androgenetic Alopecia
Interventions: KX0826, Placebo; Drug · Other
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

MS PATHS Normative Sub-Study

Safety and Tolerability of PF-06818883 in Healthy Subjects

A Phase 1 Safety and PK Study of IV TP-271

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants

Healthy Volunteer Study

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

Hutrukin to Analyze Safety and PK in Healthy Volunteers

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects

Single and Repeated Dose Escalation Study of GSK2838232

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration